Nanostics
Nanostics is a commercial-stage precision health company developing novel tools to bring clarity to healthcare decisions, specifically focusing on de-risking prostate cancer screening. Their primary product, ClarityDX Prostate, is a decision support tool that uses a machine learning platform combining clinical features and blood-based biomarkers (total PSA and free PSA) to determine a patient's risk of aggressive prostate cancer. This empowers patients and healthcare providers to make more informed decisions, aiming to reduce unnecessary prostate biopsies. The company highlights its proprietary algorithm and its ability to be integrated into existing healthcare pathways with minimal inconvenience and low cost. Nanostics has a CPSA accredited laboratory for performing these measurements.
Nanostics
Nanostics is a commercial-stage precision health company developing novel tools to bring clarity to healthcare decisions, specifically focusing on de-risking prostate cancer screening. Their primary product, ClarityDX Prostate, is a decision support tool that uses a machine learning platform combining clinical features and blood-based biomarkers (total PSA and free PSA) to determine a patient's risk of aggressive prostate cancer. This empowers patients and healthcare providers to make more informed decisions, aiming to reduce unnecessary prostate biopsies. The company highlights its proprietary algorithm and its ability to be integrated into existing healthcare pathways with minimal inconvenience and low cost. Nanostics has a CPSA accredited laboratory for performing these measurements.